On May 27, the French government revoked the decree authorizing hospitals to prescribe the prescription drug hydroxychloroquine for patients with new coronary pneumonia.
Prior to May 26, the French public health supervision agency warned that hydroxychloroquine should not be used to treat new coronary pneumonia.
According to the French state-owned television station France 24 reported on the same day, the French government ’s decision was made two days after the World Health Organization (WHO) announced the suspension of the use of hydroxychloroquine to treat the new crown experiment.
On May 22, the British “Lancet” magazine published an observation report showing that the anti-malarial drugs chloroquine or hydroxychloroquine have no obvious benefits for the treatment of new coronavirus infections. Improperness may even cause complications. According to the Xinhua News Agency report on May 25, when treating patients with new crowns, whether they use chloroquine or hydroxychloroquine alone or in combination with macrolide antibiotics, the patient’s mortality rate may be higher.
In view of this, WHO Director General Tan Desai announced on May 25 that the hydroxychloroquine branch test in the “Unity Test” project will be suspended to fully evaluate the hydroxychloroquine ’s Potential pros and cons. Tan Desai also pointed out that chloroquine or hydroxychloroquine are generally considered safe when used to treat autoimmune diseases or malaria, and this suspension is only for the new crown treatment trial process.
According to a report by China News Service on May 25, before that, US President Trump continued to take the drug hydroxychloroquine to prevent the new coronavirus, which caused huge controversy. On May 24 local time, Trump stated that he had stopped taking medication. But he also said that hydroxychloroquine “was well received” and saved many lives.